NASDAQ:SRDX Surmodics (SRDX) Stock Price, News & Analysis $29.42 +0.02 (+0.06%) As of 02:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Surmodics Stock (NASDAQ:SRDX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Surmodics alerts:Sign Up Key Stats Today's Range$27.93▼$29.4550-Day Range$26.71▼$35.9052-Week Range$25.17▼$42.44Volume23,924 shsAverage Volume277,137 shsMarket Capitalization$420.57 millionP/E RatioN/ADividend YieldN/APrice Target$50.00Consensus RatingHold Company OverviewSurmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.Read More… Surmodics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreSRDX MarketRank™: Surmodics scored higher than 83% of companies evaluated by MarketBeat, and ranked 186th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingSurmodics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageSurmodics has only been the subject of 2 research reports in the past 90 days.Read more about Surmodics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth300.00% Earnings GrowthEarnings for Surmodics are expected to grow by 300.00% in the coming year, from $0.20 to $0.80 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Surmodics is -28.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Surmodics is -28.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSurmodics has a P/B Ratio of 3.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Surmodics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.48% of the float of Surmodics has been sold short.Short Interest Ratio / Days to CoverSurmodics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Surmodics has recently increased by 11.94%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSurmodics does not currently pay a dividend.Dividend GrowthSurmodics does not have a long track record of dividend growth. Sustainability and ESG3.4 / 5Environmental Score-2.52 Percentage of Shares Shorted2.48% of the float of Surmodics has been sold short.Short Interest Ratio / Days to CoverSurmodics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Surmodics has recently increased by 11.94%, indicating that investor sentiment is decreasing significantly. News and Social Media2.9 / 5News Sentiment1.21 News SentimentSurmodics has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Surmodics this week, compared to 2 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Surmodics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.90% of the stock of Surmodics is held by insiders.Percentage Held by Institutions96.63% of the stock of Surmodics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Surmodics' insider trading history. Receive SRDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter. Email Address SRDX Stock News HeadlinesSurmodics publishes TRANSCEND trial dataApril 22 at 2:55 PM | markets.businessinsider.comSurmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated BalloonApril 22 at 7:00 AM | businesswire.comCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…April 25, 2025 | Crypto Swap Profits (Ad)Barrington Sticks to Their Hold Rating for SurModics (SRDX)April 5, 2025 | markets.businessinsider.comSurmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral ArteriesApril 3, 2025 | finance.yahoo.comSurModics (SRDX) Gets a Hold from BarringtonMarch 31, 2025 | markets.businessinsider.comLake Street Upgrades Surmodics (SRDX)March 8, 2025 | msn.comFTC sues to block acquisition of SurmodicsMarch 7, 2025 | markets.businessinsider.comSee More Headlines SRDX Stock Analysis - Frequently Asked Questions How have SRDX shares performed this year? Surmodics' stock was trading at $39.60 at the beginning of the year. Since then, SRDX stock has decreased by 27.6% and is now trading at $28.68. View the best growth stocks for 2025 here. How were Surmodics' earnings last quarter? Surmodics, Inc. (NASDAQ:SRDX) issued its earnings results on Thursday, February, 6th. The company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.04. Surmodics had a negative net margin of 11.48% and a negative trailing twelve-month return on equity of 4.39%. Who are Surmodics' major shareholders? Top institutional investors of Surmodics include Salem Investment Counselors Inc. (0.80%) and FNY Investment Advisers LLC (0.03%). Insiders that own company stock include Timothy J Arens, David Dantzker, Ronald B Sr Kalich Sr and Jose H Bedoya. View institutional ownership trends. How do I buy shares of Surmodics? Shares of SRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Surmodics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Surmodics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Palo Alto Networks (PANW). Company Calendar Last Earnings2/06/2025Today4/25/2025Next Earnings (Estimated)4/29/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:SRDX CIK924717 Webwww.surmodics.com Phone(952) 500-7000Fax952-500-7001Employees450Year Founded1979Price Target and Rating Average Stock Price Target$50.00 High Stock Price Target$71.00 Low Stock Price Target$43.00 Potential Upside/Downside+70.4%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.01) Trailing P/E RatioN/A Forward P/E Ratio146.70 P/E GrowthN/ANet Income$-11,540,000.00 Net Margins-11.48% Pretax Margin-7.75% Return on Equity-4.39% Return on Assets-2.95% Debt Debt-to-Equity Ratio0.26 Current Ratio5.45 Quick Ratio4.29 Sales & Book Value Annual Sales$125.45 million Price / Sales3.34 Cash Flow$0.26 per share Price / Cash Flow111.12 Book Value$7.82 per share Price / Book3.75Miscellaneous Outstanding Shares14,296,000Free Float13,024,000Market Cap$419.44 million OptionableOptionable Beta1.30 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (NASDAQ:SRDX) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Surmodics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Surmodics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.